Arcus Biosciences, Inc. (NYSE:RCUS) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced on 6/26/2018 that they have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types which typically show minimal response to checkpoint inhibition monotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,